Table 4.

Prognostic Value of the Percentage of Age-Predicted Maximal Heart Rate Achieved: Continuous Analysis

HR per 10% ppMHR	A. No Adjustment for Exercise Capacity	B. Adjustment for Exercise Capacity	p-value
All Patients (n=64,549)	0.84 (0.83–0.86)	0.91 (0.89–0.92)	<.001
No Beta Blocker Therapy (n=50,941)	0.80 (0.78–0.82)	0.88 (0.86–0.90)	<.001
Beta Blocker Therapy (n=13,608)	0.89 (0.87–0.92)	0.95 (0.93–0.98)	<.001

Prognostic value of percentage of age-predicted maximal heart rate, without (A) and with (B) additional adjustment for exercise capacity, stratified by use of beta-blocker therapy. Age-predicted maximal heart rate determined by 220−age, and hazard ratios results displayed as per 10% of age-predicted maximal heart rate, with 95% confidence intervals shown. P-value between beta-blocker groups. Models adjusted for age, sex, race, resting systolic and diastolic blood pressure, history of diabetes, hyperlipidemia, hypertension, obesity, smoking, coronary artery disease, percutaneous coronary intervention, coronary artery bypass graft, myocardial infarction, family history of coronary artery disease, use of medications for chronic obstructive pulmonary disease and hypertension, use of angiotensin receptor blockers, angiotensin-converting-enzyme inhibitors, calcium channel blockers, aspirin, and statins, and indication for stress testing.